Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Shares of Zoetis ZTS have risen 15.4% in the past three months compared with the industry’s 9.3% growth. The stock has also outperformed the sector as well as the S&P 500 as seen in the chart below. The stock is also trading above both its 50 and 200-day moving averages from early August.
ZTS Stock Outperforms Industry, Sector & S&P 500
Zoetis is a major player in the animal health market. The company operates in eight major product categories: vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, pain and sedation, medicated feed additives and animal health diagnostics.
Zoetis’ diversified product portfolio caters to eight core species, namely, cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Let’s delve deeper to discuss four reasons why adding Zoetis stock to your portfolio may prove beneficial in 2024.
ZTS’ New Products Deliver Strong Performance
Zoetis has built a very strong companion animal portfolio over the last several years based on its internal innovation, which contributes significantly to the top line. Key dermatology products (Apoquel and Cytopoint), new products (such as Simparica and Stronghold Plus) and increased medicalization rates in key international markets are propelling further growth. Zoetis has also received the FDA’s approval for ProHeart 12 (moxidectin), which is the industry’s only once-yearly injection to prevent heartworm disease in dogs aged 12 months or older.
Last year, the regulatory body approved Apoquel Chewable tablets in the United States for controlling pruritus related to allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Zoetis’ Apoquel Chewable is an easier-to-use formulation that has enhanced medication compliance and, therefore, improved outcomes for dogs. Hence, the demand is strong.
The approval of Simparica Trio in Europe and the United States has strengthened the company’s market-leading parasiticide portfolio for companion animals. The uptake of the product has been strong. ZTS also continues to bolster its vaccine portfolio for livestock.
Zoetis received approval for Rimadyl (carprofen) for dogs in China, which is one of the fastest-growing companion animal markets in the world. It is indicated for relief from pain and inflammation associated with osteoarthritis (chewables) and control of postoperative pain related to soft tissue and orthopedic surgeries (injectables).
The uptake of Librela and Solensia, the company’s new monoclonal antibody therapies for osteoarthritis pain in dogs and cats, is also positive and expected to continue to boost growth in upcoming quarters. Approval of other innovative products in the future, along with continued uptake of its existing products, should further boost sales in the quarters ahead.
ZTS Drives Growth Through Strategic Acquisitions
Zoetis has also been expanding its business through acquisitions. Such expansion initiatives bode well for the company, strengthening its position in the animal healthcare market.
During the third quarter of 2023, the company acquired two privately held research and development stage animal health biopharmaceutical companies, PetMedix Ltd. and adivo GmbH. PetMedix develops antibody-based therapeutics for companion animals. This acquisition is expected to strengthen Zoetis’ companion animal products portfolio.
In early 2024, Zoetis expanded the capabilities of its multi-application diagnostics platform, Vetscan Imagyst, to include AI Urine Sediment analysis. This new feature facilitates accurate, in-clinic sediment analysis of fresh urine, allowing veterinarians to make treatment decisions quickly.
Vetscan Imagyst is the first and only AI-driven diagnostics technology to provide five applications in a single platform, offering analysis at the point of care. The AI-driven nature of this additional feature offers veterinarians fast, consistent and accurate results to devise individualized treatment plans that benefit both pets and pet owners.
This new additional feature broadens the already existing wide range of high-value, in-clinic diagnostics offered by Vetscan Imagyst, thus facilitating better treatment.
ZTS’ Zacks Rank, Premium Valuation & Rising Estimates
Zoetis currently carries a Zacks Rank #2 (Buy).
The stock is currently trading at a premium to the industry, as seen in the chart below. However, it might be prudent to add ZTS to your portfolio despite the premium valuation, as the company's strong fundamentals will generate lucrative returns in the future.
In the past 60 days, the Zacks Consensus Estimate for Zoetis’ 2024 earnings per share (EPS) has increased from $5.76 to $5.83. During the same time frame, the consensus estimate for ZTS’ 2025 EPS has increased from $6.32 to $6.42.
Consistently rising earnings estimates highlight analysts’ optimistic outlook for further growth.
ZTS Boosts Shareholder Value With Increased Dividends
Zoetis has been consistently increasing dividends for shareholders, which is another lucrative reason to add the stock to your portfolio. ZTS’ board declared a dividend of $0.432 per share for the third quarter of 2024, representing an increase of 15% from the quarterly dividend rate paid in 2023.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Illumina, Inc. ILMN, Krystal Biotech, Inc. KRYS and Fulcrum Therapeutics, Inc. FULC, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Illumina’s 2024 EPS have moved up from $1.84 to $3.62. The consensus estimate for 2025 earnings has improved from $3.22 to $4.43. In the past three months, shares of ILMN have gained 20.5%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have increased from $2.09 to $2.38. The consensus estimate for 2025 earnings has improved from $4.33 to $7.31. In the past three months, shares of KRYS have jumped 9.4%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 33 cents. The consensus estimate for 2025 loss per share has narrowed from $1.71 to $1.14. In the past three months, shares of FULC have plunged 46.2%.
FULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
Zacks Investment Research
Rocket Pharmaceuticals, Inc. RCKT announced that it has completed patient enrollment in a pivotal phase II study evaluating its investigational gene therapy candidate, RP-A501, for treating male patients with Danon disease.
Danon disease is a rare X-linked inherited disorder caused by mutations in the LAMP2 gene.
Per the company, an estimated 15,000 to 30,000 patients suffer from Danon disease in the United States and Europe. Currently, the only available treatment for the disease is cardiac transplantation, which is not considered curative and may lead to complications.
Shares of the company were up 13.5% on Sept. 17 following the announcement of the news.
Year to date, shares of Rocket have plunged 27.2% against the industry’s increase of 1%.
More on RCKT’s RP-A501 Danon Disease Study
The global multi-center phase II study is evaluating the safety and efficacy of RP-A501 in male patients with Danon disease.
The co-primary endpoint of the study is to check the improvements in LAMP2 protein expression and reductions in left ventricular mass as measured by the biomarker while assessing the efficacy of RP-A501. This will be used to support the accelerated approval for RP-A501.
The key secondary endpoint of the study is to observe the change in troponin. Other secondary endpoints include natriuretic peptides event-free survival to 24 months and treatment-emergent safety events.
Per management, RP-A501 is the first gene therapy product to demonstrate safety and efficacy in clinical studies for a cardiovascular condition.
The FDA and European Medical Agency previously granted regenerative medicine advanced therapy designation and PRIority MEdicines (PRIME) scheme designation to RP-A501, respectively.
RCKT’s Other Pipeline Development Activities
The company is developing its gene therapy candidate, Kresladi (marnetegragene autotemcel), to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
In June 2024, the FDA issued a complete response letter (CRL) to Rocket’s biologics license application (BLA) seeking approval for Kresladi to treat LAD-I.
Per the CRL, the FDA sought "limited" additional information on the Chemistry Manufacturing and Controls (CMC), which is part of the BLA submission. The goal of CMC is to ensure that every batch of the final product is identical in terms of its safety, purity, potency and performance.
Rocket is also evaluating two other gene therapies, namely RP-L102 and RP-L301, for the treatment of Fanconi anemia and pyruvate kinase deficiency, respectively. Both candidates are in mid-stage development.
Zacks Rank & Stocks to Consider
Rocket currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the biotech sector are Illumina, Inc. ILMN, Krystal Biotech, Inc. KRYS and Fulcrum Therapeutics, Inc. FULC, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.84 to $3.62. Earnings per share estimates for 2025 have improved from $3.22 to $4.43. Year to date, shares of ILMN have lost 6.5%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have increased from $2.09 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 52.6%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 33 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.14. Year to date, shares of FULC have plunged 48.3%.
FULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
Zacks Investment Research
NEW YORK, NY / ACCESSWIRE / September 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FULC.
Investigation Details
On September 12, 2024, Fulcrum announced that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo. In addition, secondary endpoints did not achieve nominal statistical significance." Following this news, Fulcrum stock dropped almost 60% in morning trading on the same day.
What's Next?
If you are aware of any facts relating to this investigation or purchased Fulcrum securities, you can assist this investigation by visiting the firm's site: bgandg.com/FULC. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on accesswire.comTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Considering buying SBUX stock? Here’s what analysts think:
Read Next:
Latest Ratings for SBUX
Date | Firm | Action | From | To |
---|---|---|---|---|
Feb 2022 | Deutsche Bank | Maintains | Buy | |
Feb 2022 | MKM Partners | Maintains | Buy | |
Feb 2022 | Credit Suisse | Maintains | Outperform |
View More Analyst Ratings for SBUX
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005.
Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors.
Investor-friendly, sector ETFs provide many options to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 5, placing it in top 31%.
Index Details
The fund is sponsored by Invesco. It has amassed assets over $271.87 million, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. PBE seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index before fees and expenses.
The Dynamic Biotech & Genome Intellidex Index seeks to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value.
Costs
Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same.
Annual operating expenses for this ETF are 0.58%, making it on par with most peer products in the space.
It has a 12-month trailing dividend yield of 0.05%.
Sector Exposure and Top Holdings
Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation in the Healthcare sector--about 99.90% of the portfolio.
Looking at individual holdings, Gilead Sciences Inc (GILD) accounts for about 5.58% of total assets, followed by Illumina Inc (ILMN) and Regeneron Pharmaceuticals Inc (REGN).
The top 10 holdings account for about 48.18% of total assets under management.
Performance and Risk
So far this year, PBE return is roughly 8.14%, and was up about 20.51% in the last one year (as of 09/18/2024). During this past 52-week period, the fund has traded between $52.52 and $71.87.
The ETF has a beta of 0.80 and standard deviation of 23.55% for the trailing three-year period, making it a high risk choice in the space. With about 32 holdings, it has more concentrated exposure than peers.
Alternatives
Invesco Biotechnology & Genome ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PBE is a sufficient option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.
SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $7.70 billion in assets, iShares Biotechnology ETF has $7.73 billion. XBI has an expense ratio of 0.35% and IBB charges 0.45%.
Bottom Line
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Zacks Investment Research
LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo. In addition, secondary endpoints did not achieve nominal statistical significance." Based on this news, shares of Fulcrum fell by almost 60% in morning trading on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335info@schallfirm.comwww.schallfirm.com
SOURCE: The Schall Law Firm
View the original press release on accesswire.comWhite Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.